Abstract
It is widely accepted that blood coagulation in vivo is initiated during normal hemostasis, as well as during intravascular thrombus formation, when the cell-surface protein, tissue factor, is exposed to the blood as a consequence of vascular injury. In addition to its essential role in hemostasis, tissue factor may be also implicated in several pathophysiological processes, such as intracellular signaling, cell proliferation, and inflammation. For these reasons, the tissue factor:factor VIIa complex has been the subject of intense research focus. Many experimental studies have demonstrated that inhibition of tissue factor:factor VIIa procoagulant activity are powerful inhibitors of in vivo thrombosis and that this approach usually results in less pronounced bleeding tendency, as compared to other “more classical” antithrombotic interventions. Alternative approaches may be represented by transfecting the arterial wall with natural inhibitors of tissue factor:factor VIIa complex, such as tissue factor pathway inhibitor, which may result in complete inhibition of local thrombosis without incurring in potentially harmful systemic effects. Additional studies are warranted to determine the efficacy and safety of such approaches in patients.
Keywords: tissue factor coagulation pathway, hemostasis, tissue factor, factor VIIa procoagulant, antithrombotic interventions
Current Vascular Pharmacology
Title: Inhibition of the Tissue Factor Coagulation Pathway
Volume: 2 Issue: 4
Author(s): Paolo Golino, Lavinia Forte and Salvatore De Rosa
Affiliation:
Keywords: tissue factor coagulation pathway, hemostasis, tissue factor, factor VIIa procoagulant, antithrombotic interventions
Abstract: It is widely accepted that blood coagulation in vivo is initiated during normal hemostasis, as well as during intravascular thrombus formation, when the cell-surface protein, tissue factor, is exposed to the blood as a consequence of vascular injury. In addition to its essential role in hemostasis, tissue factor may be also implicated in several pathophysiological processes, such as intracellular signaling, cell proliferation, and inflammation. For these reasons, the tissue factor:factor VIIa complex has been the subject of intense research focus. Many experimental studies have demonstrated that inhibition of tissue factor:factor VIIa procoagulant activity are powerful inhibitors of in vivo thrombosis and that this approach usually results in less pronounced bleeding tendency, as compared to other “more classical” antithrombotic interventions. Alternative approaches may be represented by transfecting the arterial wall with natural inhibitors of tissue factor:factor VIIa complex, such as tissue factor pathway inhibitor, which may result in complete inhibition of local thrombosis without incurring in potentially harmful systemic effects. Additional studies are warranted to determine the efficacy and safety of such approaches in patients.
Export Options
About this article
Cite this article as:
Golino Paolo, Forte Lavinia and Rosa De Salvatore, Inhibition of the Tissue Factor Coagulation Pathway, Current Vascular Pharmacology 2004; 2 (4) . https://dx.doi.org/10.2174/1570161043385402
DOI https://dx.doi.org/10.2174/1570161043385402 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CYLD-Mediated Signaling and Diseases
Current Drug Targets Role of Innate Immune System in Inflammation and Cardiac Remodeling After Myocardial Infarction
Current Vascular Pharmacology Absorption, Disposition and Pharmacokinetics of Nanoemulsions
Current Drug Metabolism Fluid-Phase Pinocytosis of LDL by Macrophages: A Novel Target to Reduce Macrophage Cholesterol Accumulation in Atherosclerotic Lesions
Current Pharmaceutical Design Pediatric CKD and Cardivascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Editorial: Thematic Issue-Topic–Diabetic Cardiovascular Disease–An Unmet Medical Need: Emerging Targets and Therapies-Introduction to the Special Issue
Cardiovascular & Hematological Agents in Medicinal Chemistry Vascularization of Biomaterials for Bone Tissue Engineering: Current Approaches and Major Challenges
Current Angiogenesis (Discontinued) Microvascular Obstruction After Primary Percutaneous Coronary Intervention: Pathogenesis, Diagnosis and Prognostic Significance
Current Vascular Pharmacology Proteomics and Mass Spectrometry: What Have We Learned About The Heart?
Current Cardiology Reviews The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) New Challenges for ACE-Inhibitors in Vascular Diseases
Drug Design Reviews - Online (Discontinued) The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation
Cardiovascular & Hematological Disorders-Drug Targets Regenerative Approaches to Post-Myocardial Infarction Heart Failure
Current Pharmaceutical Design Hematopoietic Colony Stimulating Factors in Cardiovascular and Pulmonary Remodeling: Promoters or Inhibitors?
Current Pharmaceutical Design Canonical and Non-Canonical Barriers Facing AntimiR Cancer Therapeutics
Current Medicinal Chemistry Functions of S100 Proteins
Current Molecular Medicine Role of Vasa Vasorum in Arterial Disease: A Re-emerging Factor
Current Cardiology Reviews 3D CT Angiography of Infrarenal Abdominal Aortic Aneurysm with Associated Ectopic Pelvic Kidney: A Case Report of Rare Concomitance
Current Medical Imaging RNAi-Based Therapy in Experimental Ischemia-Reperfusion Injury. The New Targets
Current Pharmaceutical Design PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
Current Pharmaceutical Design